Argenx announces plans to acquire Forte Biosciences in a deal valued at $2.2 billion, according to multiple outlets. The transaction targets expansion of argenx’s immunology drug pipeline, with Forte’s assets expected to add to therapies aimed at treating multiple autoimmune diseases. One report notes the proposed purchase price represents a 41% premium to Forte’s closing price on Friday, indicating the offer is above the stock’s recent trading level. The companies are described as seeking to build on argenx’s existing work in immunology by incorporating Forte’s development programs and related pipeline capabilities. The coverage is consistent across sources on the deal size and the stated rationale of pipeline growth in immunology. However, the excerpts provided do not specify additional deal terms such as timing, regulatory approvals, financing structure, or expected completion date. Overall, the reporting centers on the announced $2.2 billion acquisition and its intended role in strengthening argenx’s pipeline for autoimmune conditions.